<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03094715</url>
  </required_header>
  <id_info>
    <org_study_id>TENSION</org_study_id>
    <nct_id>NCT03094715</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Thrombectomy in Stroke With Extended Lesion and Extended Time Window</brief_title>
  <acronym>Tension</acronym>
  <official_title>Efficacy and Safety of Thrombectomy in Stroke With Extended Lesion and Extended Time Window: a Randomized, Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Heidelberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eppdata GmbH Hamburg, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University Innsbruck</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Groupe Hospitalier Pitie-Salpetriere</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Martin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Charles University, Czech Republic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CHU de Reims</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Epidemiological and Clinical Research Information Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>STROKE ALLIANCE FOR EUROPE</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>International Consortium for Health Outcome Measurement, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Europan Society for Minimally Invasive Neurological Therapy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Heidelberg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      TENSION (Efficacy and safety of ThrombEctomy iN Stroke with extended leSION and extended time&#xD;
      window) is a prospective, open label, blinded endpoint (PROBE), European two-arm, randomized,&#xD;
      controlled, post-market study to compare the safety and effectiveness of endovascular&#xD;
      thrombectomy as compared to best medical care alone in the treatment of acute ischemic stroke&#xD;
      patients with extended stroke lesions defined by an Alberta Stroke Program Early CT Score&#xD;
      (ASPECTS) score of 3-5 and in an extended time window (up to 12 hours or unknown time of&#xD;
      symptom onset). Up to 665 subjects will be randomized. Primary endpoint will be functional&#xD;
      outcome assessed by the modified Rankin scale at 90 days post-stroke (&quot;mRS shift analysis&quot;).&#xD;
      By this, TENSION will provide evidence of efficacy and safety of thrombectomy in an acute&#xD;
      stroke population with uncertain benefit of endovascular stroke treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, open label, blinded endpoint (PROBE),European, two-arm,&#xD;
      randomized, controlled, post-market study to compare the safety and effectiveness of&#xD;
      endovascular thrombectomy as compared to best medical care alone in the treatment of acute&#xD;
      ischemic stroke (AIS) in patients with extended stroke lesions defined by an ASPECT score of&#xD;
      3-5 and in an extended time window (up to 12 hours, or unknown time of symptom onset). This&#xD;
      is an adaptive design study, with prospectively stated interim analyses with specified&#xD;
      stopping rules allowing for the possibility early termination based on either a determination&#xD;
      of study success or futility.&#xD;
&#xD;
      Up to 665 subjects will be enrolled in the study and randomized for the Intention to treat&#xD;
      analysis set. The randomization will be stratified by time from symptom onset (0-6h and&#xD;
      6-11h/wake up stroke), and stroke severity (NIHSS ≤18, NIHSS &gt;18).&#xD;
&#xD;
      Interim data analysis is planned after the primary endpoint has been obtained for one third&#xD;
      and two thirds of the patients. At each of these sample sizes, the available 90-day mRS data&#xD;
      for each treatment arm will be evaluated. Safety interim analysis will be performed after one&#xD;
      third and two thirds of the patients have been included.&#xD;
&#xD;
      Subjects who meet the inclusion criteria will be randomized in a 1:1 ratio to one of the&#xD;
      following two treatment arms:&#xD;
&#xD;
      Arm 1: best medical care Arm 2: endovascular thrombectomy and best medical care The primary&#xD;
      objective of this study is to test efficacy and safety of thrombectomy in acute stroke&#xD;
      patients with uncertain benefit of endovascular stroke treatment, i.e. extended ischemic&#xD;
      lesion size with an ASPECT score of 3-5 or late (up to 12 hours) or unknown time window as&#xD;
      compared to best medical care alone.&#xD;
&#xD;
      Approximately 40 sites in Up to 20 sites in 8-10 European countries Patients presenting with&#xD;
      acute ischemic stroke (AIS) based on focal occlusion in the M1 segment of the middle cerebral&#xD;
      artery (MCA), and/or the intracranial segment of the distal internal carotid artery (ICA),&#xD;
      determined by Magnetic Resonance Angiography (MRA) or Computed Tomographic Angiography (CTA),&#xD;
      and who meet all eligibility criteria will be considered for study enrollment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 20, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>prospective, open label, blinded endpoint (PROBE), European, two-arm, randomized, controlled, post-market study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical outcome-modified Rankin Scale at 90 days</measure>
    <time_frame>90 days</time_frame>
    <description>The primary endpoint of the trial is the modified Rankin Scale (mRS) outcome at 90 days post-stroke. The primary effectiveness endpoint analysis is a chi-square test of the difference in linear trends in ordinal mRS outcomes at 90 days post-procedure between treatment groups (&quot;mRS shift analysis&quot;).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Independence - modified Rankin Scale≤2 at 90 days</measure>
    <time_frame>90 days</time_frame>
    <description>Independent neurological outcomes with 90-day mRS≤2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Moderate Outcome - modified Rankin Scale≤3 at 90 days</measure>
    <time_frame>90 days</time_frame>
    <description>Moderate neurological outcome with 90-day mRS≤3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infarct volume 24 hours post procedure</measure>
    <time_frame>18-36 hours</time_frame>
    <description>Infarct volume at 24 hours on post-procedure imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infarct growth</measure>
    <time_frame>18-36 hours</time_frame>
    <description>Difference of infarct volume from infarct volume as predicted by pre-treatment imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional neurological outcome at 12 months - modified Rankin Scale</measure>
    <time_frame>12 month</time_frame>
    <description>Functional neurological outcome at 12 months (±14 days) after stroke (simplified modified Rankin Scale questionnaire, smRSq)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life - PROMIS-10</measure>
    <time_frame>90 days</time_frame>
    <description>Patient-Reported Outcomes Measurement Information System (PROMIS)-10 questionaire at 90 (±14) days. PROMIS Global-10 short form consists of 10 items that assess general domains of health and functioning including overall physical health, mental health, social health, pain, fatigue, and overall perceived quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life - EQ-5D</measure>
    <time_frame>90 days</time_frame>
    <description>Patient-reported functional health status and quality of life 90 (±14) days. EuroQol five-dimension scale. A standardised instrument created by the EuroQol Group as a measure of health outcome. EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each of which can take one of three responses reflecting severity (no problems/some or moderate problems/extreme problems).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-stroke depression - Patient Health Questionnaire-4</measure>
    <time_frame>90 days</time_frame>
    <description>Post-stroke depression 90 (±14) days after stroke based on the Patient Health Questionnaire-4 (PHQ-4), Patient Health Questionnaire-4, Psychological distress in PHQ-4 is being rated based on 4 questions as none (0-2&quot;) mild (3-5) moderate (6-8) severe (9-12)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parenchymal hemorrhage type 2</measure>
    <time_frame>90 days</time_frame>
    <description>blood clots in &gt;30% of the infarcted area with a substantial space-occupying effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>modified Rankin Scale between 4-6</measure>
    <time_frame>12 month</time_frame>
    <description>Death or dependency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequencies of Adverse Events (AE) in both treatment arms within the first 7 days</measure>
    <time_frame>7 days</time_frame>
    <description>Serious AEs (SAEs), overall (all-cause mortality) and stroke-related death (i.e., related to intracranial bleeding, midline shift, brain herniation, progression of stroke symptoms, or systemic complications from stroke such as pneumonia).&#xD;
Space-occupying infarction (malignant brain edema)&#xD;
New ischemic stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious AEs</measure>
    <time_frame>12 month</time_frame>
    <description>Serious AEs (SAEs), overall (all-cause mortality) and stroke-related death (i.e., related to intracranial bleeding, midline shift, brain herniation, progression of stroke symptoms, or systemic complications from stroke such as pneumonia).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Space-occupying infarction</measure>
    <time_frame>18-36 hours</time_frame>
    <description>Malignant brain edema after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New ischemic stroke</measure>
    <time_frame>12 month</time_frame>
    <description>New AIS after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic intracranial hemorrhage (sICH) at 24 (18-36) hours (CT or MRI)</measure>
    <time_frame>18-36 hours</time_frame>
    <description>sICH as defined in Safe Implementation of Treatments in Stroke-Monitoring Study (SITS-MOST)&#xD;
parenchymal hemorrhage type 2 (PH-2)&#xD;
Frequencies of Adverse Events (AE) in both treatment arms within the first 7 days after treatment&#xD;
Serious AEs (SAEs), overall (all-cause mortality) and stroke-related death (i.e., related to intracranial bleeding, midline shift, brain herniation, progression of stroke symptoms, or systemic complications from stroke such as pneumonia).&#xD;
Space-occupying infarction (malignant brain edema)&#xD;
New ischemic stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost Utility Assessment</measure>
    <time_frame>12 month</time_frame>
    <description>Assessment of costs from the time of randomization to the 12-months follow-up, including costs of hospitalization, institutionalized living, outpatient care, informal care provided by relatives and cost of lost productivity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life - PROMIS-10</measure>
    <time_frame>12 month</time_frame>
    <description>Patient-Reported Outcomes Measurement Information System (PROMIS)-10 questionaire at 12 month (±14 days). PROMIS Global-10 short form consists of 10 items that assess general domains of health and functioning including overall physical health, mental health, social health, pain, fatigue, and overall perceived quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life - EQ-5D</measure>
    <time_frame>12 month</time_frame>
    <description>Health related quality of life assessment at 12 months (±14 days). EuroQol five-dimension scale. A standardised instrument created by the EuroQol Group as a measure of health outcome. EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each of which can take one of three responses reflecting severity (no problems/some or moderate problems/extreme problems).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-stroke depression - Patient Health Questionnaire-4</measure>
    <time_frame>12 month</time_frame>
    <description>Health related quality of life assessment at 12 months (±14 days) to assess post stroke depression - Patient Health Questionnaire-4 (PHQ-4) Psychological distress in PHQ-4 is being rated based on 4 questions as none (0-2&quot;) mild (3-5) moderate (6-8) severe (9-12)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">665</enrollment>
  <condition>Stroke, Acute</condition>
  <condition>Cerebral Stroke</condition>
  <condition>Cerebrovascular Stroke</condition>
  <condition>Apoplexy; Brain</condition>
  <arm_group>
    <arm_group_label>Thrombectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Endovascular thrombectomy and best medical care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Best medical care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Best medical treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Thrombectomy</intervention_name>
    <description>Mechanical thrombectomy with state of the art thrombectomy devices (i.e. stent-retrievers, aspiration catheters). Devices will be used per instructions for use (IFU).</description>
    <arm_group_label>Thrombectomy</arm_group_label>
    <other_name>Mechanical thrombectomy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Best medical care</intervention_name>
    <description>Best medical treatment will be performed as detailed in established Standard Operating Procedures, following regional guidelines (American Heart Association (AHA), European Stroke Organisation (ESO), Deutsche Schlaganfall-Gesellschaft (DSG), local country, etc.). If applicable, the reason for iv tissue plasminogen activator (tPA) ineligibility has to be documented on the eCRF.</description>
    <arm_group_label>Best medical care</arm_group_label>
    <other_name>Control group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Randomization within 11 hours after stroke onset (if known) or last seen well.&#xD;
&#xD;
          -  Endovascular treatment is expected to be finished within 12 hours after known symptom&#xD;
             onset or last seen well by judgment of the interventional neuroradiologist in charge&#xD;
             (if stroke onset is known).&#xD;
&#xD;
          -  Patient must demonstrate clinical signs and symptoms attributable to target area of&#xD;
             occlusion consistent with the diagnosis of ischemic stroke, including impairment of&#xD;
             the following: language, motor function, sensation, cognition, gaze, and/or vision for&#xD;
             at least 30 minutes without relevant improvement.&#xD;
&#xD;
          -  Female and male patient above 18 years of age&#xD;
&#xD;
          -  NIHSS Score of &lt;26&#xD;
&#xD;
          -  Signed informed consent (IC) form by patient or legal guardian, or inclusion of&#xD;
             patient's presumptive will by investigator under emergency situation, but after&#xD;
             consultation of an independent physician who is familiar with these types of illness&#xD;
             if the other options are not possible according to local approval.&#xD;
&#xD;
          -  Prior to new focal neurological deficit, mRS score was ≤2.&#xD;
&#xD;
        Imaging Inclusion Criteria&#xD;
&#xD;
          -  A new focal occlusion confirmed by imaging (MRA/CTA) to be accessible to the&#xD;
             thrombectomy device, and located in the M1 of the middle cerebral artery (MCA) and/or&#xD;
             the intracranial segment of the distal internal carotid artery (ICA).&#xD;
&#xD;
          -  CT (non-contrast CT) or DWI with an ASPECT score of 3-5&#xD;
&#xD;
        Clinical exclusion criteria&#xD;
&#xD;
          -  Patient is an active participant in another drug or device treatment trial for any&#xD;
             disease state or patient is expected to start participation in another drug or device&#xD;
             treatment trial while enrolled in this protocol, unless approved by Sponsor.&#xD;
&#xD;
          -  Patient has pre-existing neurological or psychiatric disease that could impede the&#xD;
             study results or would confound the neurological or functional evaluations.&#xD;
&#xD;
          -  Patient has vascular disease preventing endovascular treatment (e.g. aortic dissection&#xD;
             or aneurysm, no arterial transfemoral access)&#xD;
&#xD;
          -  Patient has history of contraindication for contrast medium.&#xD;
&#xD;
          -  Patient is known to have infective endocarditis&#xD;
&#xD;
          -  Patient's anticipated life expectancy is less than 6 Months12 months&#xD;
&#xD;
        Imaging exclusion criteria&#xD;
&#xD;
          -  ExtracaranialExtracranial CT scan or MR angiography showing high grade stenosis&#xD;
             expected to require acute stent placement (especially e.g. ICAACI stenting) during the&#xD;
             procedure to get access to the occlusion&#xD;
&#xD;
          -  CT or MRI with evidence of: Mass mass effect or intracranial tumor, or hypodensity on&#xD;
             unenhanced CT and&#xD;
&#xD;
          -  If CT perfusion is done per institutional standard: CBV drop on CBV maps on CTP, or,&#xD;
             alternatively as with an ASPECT score of 0-2&#xD;
&#xD;
          -  If DWI is done per institutional standard,: restricted diffusion on DWI with an ASPECT&#xD;
             score of 0-2, or above 5&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Götz Thomalla, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Coordination and Project Management Tension, Neurology, UKE Hamburg, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin Bendszus, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Central Trial Management Tension, Neuroradiology, UHHeidelberg, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Susanne Bonekamp, DVM, PhD</last_name>
    <phone>+49 6221 5635710</phone>
    <email>susanne.bonekamp@med.uni-heidelberg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sylvia P Danner</last_name>
    <phone>+49 6221 56-35197</phone>
    <email>Sylvia.Danner@med.uni-heidelberg.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Division of Neuroradiology, Vascular and Interventional Radiology, Department of Radiology, Medical University Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hannes Deutschmann, Prof. Dr.</last_name>
      <phone>+43(0)31638583271</phone>
      <email>hannes.deutschmann@medunigraz.at</email>
    </contact>
    <investigator>
      <last_name>Hannes Deutschmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elke R Gizewski, Prof. Dr.</last_name>
      <phone>+43 (0)512/504-27095</phone>
      <email>elke.gizewski@i-med.ac.at</email>
    </contact>
    <investigator>
      <last_name>Elke Gizewski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neuroradiology, Keppler University Hospital Linz</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johannes Trenkler, Prim. Dr.</last_name>
      <phone>*43 (0)5 7680 87 26701</phone>
      <email>johannes.trenkler@kepleruniklinikum.at</email>
    </contact>
    <investigator>
      <last_name>Johannes Trenkler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Reseach Institute of Neurointervention, Christian Doppler Clinic, Paracelsus Medical University Salzburg</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monika Killer, Prof. Dr.</last_name>
      <phone>+43(0)664 448356058</phone>
      <email>m.killer@salk.at</email>
    </contact>
    <investigator>
      <last_name>Monika Killer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 1N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael D Hill, MD</last_name>
      <email>hillmd@ucalgary.ca</email>
    </contact>
    <investigator>
      <last_name>Michael D Hill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Anne's University Hospital Brno</name>
      <address>
        <city>Brno</city>
        <zip>65691</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kateřina Martináková, MD</last_name>
      <phone>00420543183034</phone>
      <email>katerina.martinakova@fnusa.cz</email>
    </contact>
    <investigator>
      <last_name>Kateřina Martináková, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Faculty Hospital Hradec Kralove</name>
      <address>
        <city>Hradec Kralove,</city>
        <zip>50005</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonin Krajina, MD</last_name>
      <phone>00420602819174</phone>
      <email>antonin.krajina@fnhk.cz</email>
    </contact>
    <investigator>
      <last_name>Antonín Krajina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Comprehensive stroke center,University Hospital Ostrava</name>
      <address>
        <city>Ostrava</city>
        <zip>70852</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Roubec, MD</last_name>
      <phone>00420597375630</phone>
      <email>martin.roubec@fno.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Homolka Hospital Prague</name>
      <address>
        <city>Prague</city>
        <zip>150 30</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Kovar, MD</last_name>
      <phone>00420739323104</phone>
      <email>Martin.Kovar@homolka.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Radiology, Masaryk hospital</name>
      <address>
        <city>Usti nad Labem</city>
        <zip>40003</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cihlář Filip, MD; PhD</last_name>
      <phone>00420732572769</phone>
      <email>filip.cihlar@kzcr.eu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Boris Modrau, MD</last_name>
      <email>boris.modrau@rn.dk</email>
    </contact>
    <investigator>
      <last_name>Boris Modrau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claus Z Simonsen, MD</last_name>
      <phone>004550240543</phone>
      <email>clasim@rm.dk</email>
    </contact>
    <investigator>
      <last_name>Claus Z Simonsen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Goetz Benndorf, MD</last_name>
      <email>goetz.benndorf@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Gabriel Montpied, Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel Chabert, MD</last_name>
      <email>echabert@chu-clermontferrand.frcom</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpiteaux Universitaires Paris-Sud, Hôpital Bicêtre</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurent Spelle, MD</last_name>
      <phone>+33 1 45 21 73 81</phone>
      <email>laurent@spelle.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frederic Clarençon, MD, Pr</last_name>
      <email>fredclare5@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Université Reims Champagne Ardenne/ Department of Neuroradiology, Hôpital Maison Blanche</name>
      <address>
        <city>Reims</city>
        <zip>51100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent Pierot, MD</last_name>
      <phone>0033 3 26 91 30 00</phone>
      <email>lpierot@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes/Centre Urgences-Réanimations</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Yves Gauvrit, MD</last_name>
      <phone>'+33 2 99 28 42 61</phone>
      <email>jean-yves.gauvrit@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Christophe Ferré, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Hôpiteaux de Tours / Hôpital Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denis Herbreteau, MD</last_name>
      <phone>'+33 2 47 47 38 65</phone>
      <email>herbreteau@med.univ-tours.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsinstitut für Diagnostische Radiologie, Neuroradiologie und Nuklearmedizin Johannes Wesling Klinikum Minden</name>
      <address>
        <city>Minden</city>
        <state>Nordrhein-Westfalen</state>
        <zip>32429</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jan Borggrefe, Prof. Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Christoph Mönninghoff, PD Dr.</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Otto-von-Guericke-University Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <state>Sachsen-Anhalt</state>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Behme, Priv.-Doz. Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum KK Bochum-Langendreer Institut für Diagnostische und Interventionelle Radiologie, Neuroradiologie und Nuklearmedizin</name>
      <address>
        <city>Bochum</city>
        <zip>44892</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Werner Weber, MS</last_name>
      <phone>0049 (234) 299-3801</phone>
      <email>werner.weber@kk-bochum.de</email>
    </contact>
    <investigator>
      <last_name>Sebastian Fischer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabor Petzold, Prof, MD</last_name>
      <email>Gabor.Petzold@dzne.de</email>
    </contact>
    <contact_backup>
      <last_name>Ulla Jones</last_name>
      <email>ulla.jones@ukbonn.de</email>
    </contact_backup>
    <investigator>
      <last_name>Gabor Petzold, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gesundheit Nord gGmbH Klinikverbund Bremen</name>
      <address>
        <city>Bremen</city>
        <zip>28211</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Kastrup, Prof., Dr.</last_name>
      <phone>0049 4214082523</phone>
      <email>Andreas.Kastrup@klinikum-bremen-ost.de</email>
    </contact>
    <contact_backup>
      <last_name>Halil Merdivan</last_name>
      <phone>+49 (0)421 497</phone>
      <phone_ext>2675</phone_ext>
      <email>halil.merdivan@klinikum-bremen-mitte.de</email>
    </contact_backup>
    <investigator>
      <last_name>Panagiotis Papanagiotou, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andreas Kastrup, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik für Radiologie und Neuroradiologie am Klinikum Mitte</name>
      <address>
        <city>Dortmund</city>
        <zip>44137</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Rhode, Prof Dr</last_name>
      <phone>0049231 95318601</phone>
      <email>stefan.rohde@klinikumdo.de</email>
    </contact>
    <investigator>
      <last_name>Stefan Rhode, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johannes Gerber, MD</last_name>
      <phone>+49 (351) 458 2660</phone>
      <email>johannes.Gerber@uniklinikum-dresden.de</email>
    </contact>
    <investigator>
      <last_name>Johannes Gerber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alfried Krupp Krankenhaus Rüttenscheid</name>
      <address>
        <city>Essen</city>
        <zip>45131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Diakonissenkrankenhaus Flensburg</name>
      <address>
        <city>Flensburg</city>
        <zip>24939</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silke Hopf-Jensen, MD</last_name>
      <email>hopfsi@diako.de</email>
    </contact>
    <contact_backup>
      <last_name>Stefan Müller-Hülsbeck, Prof MD</last_name>
      <email>muehue@diako.de</email>
    </contact_backup>
    <investigator>
      <last_name>Stefan Müller-Hülsbeck, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20251</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jens Fiehler, Prof Dr</last_name>
      <phone>+49 (0) 40 7410 - 55598</phone>
      <email>fiehler@uke.de</email>
    </contact>
    <contact_backup>
      <last_name>Caspar Brekenfeld, PD, Dr</last_name>
      <email>c.brekenfeld@uke.de</email>
    </contact_backup>
    <investigator>
      <last_name>Caspar Brekenfeld, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neuroradiologie Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Bendszus, MD</last_name>
      <phone>00496221 567566</phone>
      <email>martin.bendszus@med.uni-heidelberg.de</email>
    </contact>
    <contact_backup>
      <last_name>Sabine Johnson</last_name>
      <email>Sabine.Johnson@med.uni-heidelberg.de</email>
    </contact_backup>
    <investigator>
      <last_name>Martin Bendszus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Liebig, Prof Dr</last_name>
      <phone>0049 89 4400 72501</phone>
      <email>sek.neurorad@med.uni-muenchen.de</email>
    </contact>
    <investigator>
      <last_name>Thomas Liebig, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Technische Universität München / Klinikum rechts der Isar</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mirko Pham, Prof Dr</last_name>
      <phone>004993120134791</phone>
      <email>pham_m@ukw.de</email>
    </contact>
    <investigator>
      <last_name>Mirko Pham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>NO-0407</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eivind Berge, MD</last_name>
      <phone>(+47) 22119100</phone>
      <email>eivind.berge@medisin.uio.no</email>
    </contact>
    <investigator>
      <last_name>Anne Hege Aamodt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Comenius University's Jessenius Faculty of Medicine and University Hospital</name>
      <address>
        <city>Martin</city>
        <zip>03659</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>K Zeleňák, MD</last_name>
      <phone>+ 421 904 164 847</phone>
      <email>zelenak@jfmed.uniba.sk</email>
    </contact>
    <investigator>
      <last_name>Kamil Zeleňák, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Faculty Hospital Trnava</name>
      <address>
        <city>Trnava</city>
        <zip>91775</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jozef Haring, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Andrej Klepanec, PhD MPH EBIR</last_name>
      <email>andrej.klepanec@fntt.sk</email>
    </contact_backup>
    <investigator>
      <last_name>Jozef Haring, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrej Klepanec, PhD, MPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>La Princesa University Hospital</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>José Vivancos Mora, MD</last_name>
      <email>joseaurelio.vivancos@salud.madrid.org</email>
    </contact>
    <contact_backup>
      <last_name>Jose Luis Caniego, MD</last_name>
      <email>jlcaniego@hotmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Gregorio Marañón University Hospital</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antonio Gil Núñez, MD</last_name>
      <email>gilnuneza@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Mariano del Valle, MD</last_name>
      <email>marianodelvalle83@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Ramón y Cajal University Hospital</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jaime Masjuan, MD</last_name>
      <email>jaime.masjuan@salud.madrid.org</email>
    </contact>
    <contact_backup>
      <last_name>J Carlos Méndez, MD</last_name>
      <email>jmendezce@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>José Egido, MD</last_name>
      <email>jegidoh@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Manuel Moreu, MD</last_name>
      <email>manumoreu@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patricia Calleja, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>La Paz University Hospital</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Blanca Fuentes Gimeno, MD</last_name>
      <email>blanca.fuentes@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>Blanca Fuentes Gimeno, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Puerta de Hierro</name>
      <address>
        <city>Madrid</city>
        <zip>28220</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joaquin Carneado, MD</last_name>
      <email>jcarnead@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Aurelio Vega, MD</last_name>
      <email>aastubil@movistar.es</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Norway</country>
    <country>Slovakia</country>
    <country>Spain</country>
  </location_countries>
  <removed_countries>
    <country>Sweden</country>
  </removed_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 16, 2017</study_first_submitted>
  <study_first_submitted_qc>March 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2017</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Heidelberg</investigator_affiliation>
    <investigator_full_name>Martin Bendszus</investigator_full_name>
    <investigator_title>Central trial management, Coordinating investigator</investigator_title>
  </responsible_party>
  <keyword>Mechanical thrombectomy</keyword>
  <keyword>Endovascular thrombectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_url>https://tension-study.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

